Natriuretic Peptides and Remodeling in Heart Failure

Heart Failure Clinics

Volumn 1, Issue 1, 2005, Pages 129-139

  Burnett Jr , John C ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALDOSTERONE ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR ANTAGONIST; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; N ACETYL S NITROSOPENICILLAMINE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; OMAPATRILAT; SPIRONOLACTONE; UNCLASSIFIED DRUG; URODILATIN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; LOW DRUG DOSE; NONHUMAN; POTASSIUM EXCRETION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT;

ALDOSTERONE; ANIMALS; CARDIOTONIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMYOCARDIAL FIBROSIS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; SODIUM; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 33645957347     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.01.002     Document Type: Review

References (91)

1. DeBold A., Borenstein H.B., Veress A.T., et al. A rapid and potent antriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 (1981) 89-94
2. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1412
3. Stingo A.J., Clavell A.L., Heublein D.M., et al. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 263 (1992) 1318-1321
4. Suga S.I., Nakao K., Itoh H., Komatsu Y., Ogawa Y., Hama N., et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system.". J Clin Invest 90 (1992) 1145-1149
5. Chinkers M. Regulation of the atrial natriuretic peptide receptor guanylyl cyclase. Proc Soc Exp Biol Med 213 (1996) 105-108
6. Charles C.J., Espiner E.A., Nicholls M.G., et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 271 (1996) R373-R380
7. Chen H.H., Lainchbury J.G., Harty G.J., et al. Maximizing the natriuretic peptide system in experimental heart failure. Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 105 (2002) 999-1003
8. Burnett Jr. J.C., Granger J.P., and Opgenorth T.F. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 247 (1984) F863-F866
9. Kishimoto I., Dubois S.K., and Garbers D.L. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci U S A 93 (1996) 6215-6219
10. Lopez M.J., Wong S.K.F., Kishimoto I., et al. Salt-resistant hypertension I mice lacking guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378 (1995) 65-68
11. Wright R.S., Wei C.M., Kim C.H., et al. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. J Am Coll Cardiol 28 (1996) 1031-1038
12. Lainchbury J.G., Burnett Jr. J.C., Meyer D., et al. Effects of the natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol 278 (2000) H33-H40
13. Yamamoto K., Burnett Jr. J.C., and Redfield M.M. Effects of endogenous natriuretic peptide system on ventricular and coronary function in the failing canine heart. Am J Physiol 273 (1997) H2406-H2414
14. Hobbs R.E., Mills R.M., and Young J.B. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Invest Drugs 10 (2001) 935-942
15. Boerrigter G., and Burnett Jr. J.C. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Invest Drugs 13 (2004) 643-652
16. Chen H.H., and Burnett J.C. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 111 (1999) 406-416
17. Colucci W.S., Elkayam U., Horton D.P., et al., The Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
18. Marcus L.S., Hart D., Packer Yushak M., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind placebo controlled, randomized crossover trial. Circulation 94 (1996) 3184-3189
19. Publication Committee for the VMAC Investigators. (Vasodilation in the Management of Acute Heart CHF). Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. J Am Med Assoc 287 (2002) 1531-1540
20. Chen H.H., Cataliotti A., Schirger J.A., et al. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol (2004) [Epub ahead of print]
21. Clavell A.L., Stingo A.J., Wei C.-M., et al. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 264 Regulatory Integrative Comp Physiol 33 (1993) R290-R295
22. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210
23. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
24. Margulies K.B., Perrella M.A., Heublein D.M., et al. ANF-mediated renal cyclic GMP generation in congestive heart failure. Am J Phyiol 260 (1991) F562-F568
25. Wang D.J., Dowling T.C., Meadows D., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110 (2004) 1620-1625
26. Kudo T., and Baird A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature 312 (1984) 756-757
27. Higuchi K., Hashiguchi T., Ohashi M., et al. Porcine brain natriuretic peptide receptor in bovine adrenal cortex. Life Sci 44 (1989) 881-886
28. Chartier L., Schiffrin E., Thibault G., et al. Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin II, ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo. Endocrinology 115 (1984) 2026-2028
29. Nawata H., Ohashi M., Haji M., et al. Atrial and brain natriuretic peptide in adrenal steroidogenesis. J Steroid Biochem Mol Biol 40 (1991) 367-379
30. Cataliotti A., Boerrigter G., Costello-Boerrigter L.C., et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 109 (2004) 1680-1685
31. Cataliotti A., Chen H.H., Harty G.J., et al. Differential cardiorenal and humoral actions of a vasopeptidase inhibitor compared to ACE inhibitor and diuretic in experimental mild CHF. Circulation 105 (2002) 639-644
32. Domanski M., Norman J., Pitt B., et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 42 (2003) 705-708
33. McCurley J.M., Hanlon S.U., Wei S.K., et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 44 (2004) 1301-1307
34. Lopez B., Querejeta R., Gonzalez A., et al. Effects of loop diuretics on myocardial fibrosis and collagen type-1 turnover in chronic heart failure. J Am Coll Cardiol 43 (2004) 2028-2035
35. Stasch J.P., Becker E.M., Alonso-Alija C., et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 410 (2001) 212-215
36. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107 (2003) 686-689
37. Michaels A.D., Klein A., Madden J.A., et al. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 107 (2003) 2697-2701
38. Molkentin J.D. A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest 111 (2003) 1275-1277
39. Holtwick R., van Eickels M., Skryabin B.V., et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111 (2003) 1399-1407
40. Tamura N., Ogawa Y., Chusho H., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 97 (2000) 4239-4244
41. Pitt B., Zannad F., Remme W.J., et al., for The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (2001) 709-717
42. Pitt B., Remme W., Zannad F., et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
43. Burlew B., and Weber K.T. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27 (2002) 92-98
44. Frohlich E.D., Apstein C., Chobanian A.V., et al. The heart in hypertension. N Engl J Med 327 (1992) 998-1008
45. Manabe I., Shido T., and Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91 (2002) 1103-1113
46. Kohl P. Heterogenous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ Res 93 (2003) 381-383
47. Cha Y.-M., Dzeja P.P., Shen W.K., et al. Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability. Am J Physiol Heart Circ Physiol 284 (2003) H1313-H1320
48. Frank J.S., and Langer G.A. The myocardial interstitium: its structure and its role in ionic exchange. J Cell Biol 60 (1974) 586-601
49. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
50. Tsuruda T., Costello-Boerrigter L.C., and Burnett Jr. J.C. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 9 (2004) 53-60
51. Zannad F., Dousset B., and Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 38 (2001) 1227-1232
52. Tsuruda T., Jougasaki M., Boerrigter G., et al. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type-A receptor. Circ Res 90 (2002) 128-134
53. Pennica D., King K.L., Shaw K.J., et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A 92 (1995) 1142-1146
54. Fukuzawa J., Booz G.W., Hunt R.A., et al. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension 35 (2000) 1191-1196
55. Sheng Z., Knowlton K., Chen J., et al. Cardiotrophin-1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway: divergence from downstreat CT-1 signals for myocardial cell hypertrophy. J Bio Chem 272 (1997) 5783-5791
56. Jougasaki M., Larsen A.M., Cataliotti A., et al. Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells. Peptides 23 (2002) 1441-1447
57. Fujisaki H., Itoh H., Hirata Y., et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 96 (1995) 1059-1065
58. Horio T., Tokodume T., Maki T., et al. Gene expression, secretion, and autocrine actions of C-type natriuretic peptide in cultured adult rat cardiac fibrosis. Endocrinology 144 (2003) 2279-2284
59. Calderone A., Thaik C.M., Takahashi N., et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101 (1998) 812-818
60. Tsuruda T., Boerrigter G., Huntley B.K., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 (2002) 1127-1134
61. Kapoun A., Liang F., O'Young G., et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts: fibrosis, myofibroblast convsion, proliferation, and inflammation. Circ Res 94 (2004) 334-342
62. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 5 (2004) 27-36
63. Kronemann N., Nockher W.A., Busse R., et al. Growth-inhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: effect on cell cycle and cyclin expression. Br J Pharmacol 126 (1999) 349-357
64. 1 to S phase of the cell cycle depends upon multiple protein interaction. J Biol Chem 273 (1998) 13966-13972
65. Burnett Jr. J.C., Kao P.C., Hu D.C., et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231 (1986) 1145-1147
66. Luchner A., Stevens T.L., Borgeson D.D., et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274 (1998) H1684-H1689
67. Stevens T.L., Burnett Jr. J.C., Kinoshita M., et al. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Inv 95 (1995) 1101-1108
68. Stevens T.L., Rasmussen T.E., Wei C.-M., et al. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Card Fail 2 (1996) 119-125
69. Wada A., Tsutamoto T., Matsuda Y., et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 89 (1994) 2232-2240
70. Lee S.-C., Stevens T.L., Sandberg S.M., et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association Class during the outpatient treatment of heart failure. J Card Fail 8 (2002) 149-154
71. Chen H.H., Grantham A., Schirger J., et al. Subcutaneous administration of BNP in experimental heart failure. J Am Coll Cardio 36 (2000) 1706-1712
72. Chen H.H., Redfield M.M., Nordstrom L.J., et al. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 10 (2004) 115-119
73. Yancy C.W., Salzberg M.T., Berkowitz R.L., et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION Trial). Am J Cardiol 94 (2004) 595-601
74. Maisel A.S., Krisnaswamy P., Nowak R.M., et al., Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
75. Cataliotti A., Malatino L., Jougasaki M., et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 76 (2001) 1111-1119
76. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105 (2002) 595-601 [erratum: Circulation 2002;106:387]
77. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
78. McCullough P.A., Nowak R.M., McCord J., Krishnaswamy P., Kazanegra R., Maisel A., et al., for the BNP Multinational Study Investigators. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106 (2002) 416-422
79. Yamamoto K., Burnett J.C., Bermudez E.A., et al. Clinical criteria and biochemical marker for the detection of systolic dysfunction. J Card Fail 6 (2000) 194-199
80. Costello-Boerrigter L.C., Redfield M.M., Rodeheffer R.J., et al. NT-proBNP is superior to BNP in the detection of left ventricular systolic dysfunction in the community. Circulation 110 Suppl III (2004) 368
81. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004) 594-600
82. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
83. Yandle T.G., Richards A.M., Gilbert A., et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 76 (1993) 832-838
84. Shimizu H., Masuta K., Asada H., et al. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 334 (2003) 233-239
85. Shimizu H., Masuta K., Aono K., et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 316 (2002) 129-135
86. Wei C.M., Kao P.C., Lin J.-T., et al. Heart failure: circulating beta atrial natriuretic factor in congestive heart failure in humans. Circulation 88 (1993) 1016-1020
87. Langenickel T.H., Pagel I., Buttergereit J., et al. Rat corin gene: molecular cloning and reduced expression in experimental heart failure. Am J Physiol Heart Circ Physiol 287 (2004) H1516-H1521
88. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. J Am Med Assoc 289 (2003) 194-202
89. Levy D., Kenchaiah S., Larson M.G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 (2002) 1397-1402
90. McDonagh T.A., Morrison C.E., Lawrence A., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350 (1997) 829-833
91. Wang T.J., Evans J.C., Benjamin E.J., et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108 (2003) 977-982